For a long time I've held the hypothesis that a snowball in clinical data relating to CardioCel will translate into a snowball in revenues...... and for a long time I have been wrong.
Revenue growth quarter to quarter for the last 4 has been impressive in a minor way. Off the top of my head $400k, $600k, $750k $800k.... growth, but not the growth I was looking for.
The paradigm has now shifted.
$800k to $1.5 million is an outstanding result and exactly the type of growth I've been expecting from a technology which offers so many compelling incentives (both financially and operationally.) The majority of us here know these incentives so I wont waste your time repeating them.
A 90% increase in CardioCel revenues, quarter to quarter, relating to the world's gold standard product cannot be ignored. Especially so when we're selling into markets in the $billions, especially so when we're now entering into a market (aortic valve reconstruction) where we'll literally be the stand alone technology in that market, especially so when at every conference we attend we arrive to greater acclaim and greater acknowledgment that the CardioCel patch is the future of patch related cardiac surgery.
We have a very exciting 12months ahead, this is a global giant in the making.
For a long time I've held the hypothesis that a snowball in...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
-0.050(0.25%) |
Mkt cap ! $387.7M | |||
| Open | High | Low | Value | Volume |
| $20.20 | $20.50 | $20.00 | $71.28K | 3.532K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 776 | $20.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.18 | 1200 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.16 |
Change
-0.050 ( 0.69 %) |
||||
| Open | High | Low | Volume | ||
| $20.17 | $20.17 | $20.09 | 129 | ||
| Last updated 15.56pm 16/05/2024 ? | |||||
| AVR (ASX) Chart |